Greywolf
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognise or target cells correctly. Greywolf are progressing a new class of antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Their technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.
Technology to solve immune dysfunction
Greywolf are developing a new therapeutic class of antigen modulators to treat people living with autoimmune disorders, cancer and infectious diseases.
A new therapeutic branch
Greywolf are the first to explore the untapped potential of changing signal 1, despite its fundamental importance in T cell activation.
Robust clinical data
Their first antigen modulator (GWRD5769) has delivered a robust response during phase I/II trial in oncology, demonstrating proof-of-mechanism and target engagement.
.png)
